Literature DB >> 16525059

Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice.

Zhi Shan Li1, Claudia Schmauss, Abigail Cuenca, Elyanne Ratcliffe, Michael D Gershon.   

Abstract

Dopaminergic neurons are present in both plexuses of the murine bowel and are upregulated after extrinsic denervation but play unknown roles in enteric nervous system (ENS) physiology. Transcripts encoding dopamine (DA) receptors D1-D5 were analyzed by reverse transcription-PCR in stomach approximately duodenum approximately ileum approximately proximal > > distal colon. Dissected muscle and myenteric plexus contained transcripts encoding D1-D3 and D5, whereas mucosa contained D1 and D3-D5. D1-D5 expression began in fetal gut [embryonic day 10 (E10)], before the appearance of neurons (E12), and was sustained without developmental regulation through postnatal day 1. In situ hybridization revealed that subsets of submucosal and myenteric neurons contained mRNA encoding D2 or D3. Immunoblots confirmed that D1, D2, and D5 receptor proteins were present from stomach through distal colon. Subsets of submucosal and myenteric neurons were also D1, D2, or D3 immunoreactive. When double labeled by in situ hybridization, these neurons contained mRNA encoding the respective receptors. Total gastrointestinal transit time (TGTT) and colonic transit time (CTT) were measured in mice lacking D2, D3, or D2 plus D3. Both TGTT and CTT were decreased significantly (motility increased) in D2 and D2 plus D3, but not D3, knock-out animals. Mice lacking D2 and D2 plus D3 but not D3 were smaller than wild-type littermates, yet ate significantly more and had greater stool frequency, water content, and mass. Because motility is abnormal when D2 is absent, the net inhibitory DA effect on motility is physiologically significant. The early expression of DA receptors is also consistent with the possibility that DA affects ENS development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16525059      PMCID: PMC6675162          DOI: 10.1523/JNEUROSCI.4720-05.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  49 in total

1.  Potentiation of the D2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors.

Authors:  M Y Jung; B V Skryabin; M Arai; S Abbondanzo; D Fu; J Brosius; N K Robakis; H G Polites; J E Pintar; C Schmauss
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

Review 2.  Neurotransmission at the interface of sympathetic and enteric divisions of the autonomic nervous system.

Authors:  J D Wood
Journal:  Chin J Physiol       Date:  1999-12-31       Impact factor: 1.764

3.  Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.

Authors:  S A Müller-Lissner; I Fumagalli; K D Bardhan; F Pace; E Pecher; B Nault; P Rüegg
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

4.  The peristaltic reflex: an analysis of the nerve pathways and their pharmacology.

Authors:  M Costa; J B Furness
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-07       Impact factor: 3.000

5.  Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.

Authors:  C M Prather; M Camilleri; A R Zinsmeister; S McKinzie; G Thomforde
Journal:  Gastroenterology       Date:  2000-03       Impact factor: 22.682

6.  Glutamate modulates neurotransmission in the submucosal plexus of guinea-pig small intestine.

Authors:  J Ren; H Z Hu; S Liu; Y Xia; J D Wood
Journal:  Neuroreport       Date:  1999-09-29       Impact factor: 1.837

Review 7.  Domperidone: a peripherally acting dopamine2-receptor antagonist.

Authors:  J A Barone
Journal:  Ann Pharmacother       Date:  1999-04       Impact factor: 3.154

8.  Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters.

Authors:  J J Chen; Z Li; H Pan; D L Murphy; H Tamir; H Koepsell; M D Gershon
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

9.  Mice lacking the dopamine transporter display altered regulation of distal colonic motility.

Authors:  J K Walker; R R Gainetdinov; A W Mangel; M G Caron; M A Shetzline
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-08       Impact factor: 4.052

10.  Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders.

Authors:  B Drolet; G Rousseau; P Daleau; R Cardinal; J Turgeon
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

View more
  81 in total

1.  Enteric neuronal density contributes to the severity of intestinal inflammation.

Authors:  Kara Gross Margolis; Korey Stevanovic; Nima Karamooz; Zi Shan Li; Ankur Ahuja; Fabien D'Autréaux; Virginia Saurman; Alcmene Chalazonitis; Michael David Gershon
Journal:  Gastroenterology       Date:  2011-04-28       Impact factor: 22.682

2.  Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling.

Authors:  Mallappa Anitha; Matam Vijay-Kumar; Shanthi V Sitaraman; Andrew T Gewirtz; Shanthi Srinivasan
Journal:  Gastroenterology       Date:  2012-06-23       Impact factor: 22.682

3.  Homeodomain interacting protein kinase 2 regulates postnatal development of enteric dopaminergic neurons and glia via BMP signaling.

Authors:  Alcmène Chalazonitis; Amy A Tang; Yulei Shang; Tuan D Pham; Ivy Hsieh; Wanda Setlik; Michael D Gershon; Eric J Huang
Journal:  J Neurosci       Date:  2011-09-28       Impact factor: 6.167

4.  Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer.

Authors:  D C Borcherding; W Tong; E R Hugo; D F Barnard; S Fox; K LaSance; E Shaughnessy; N Ben-Jonathan
Journal:  Oncogene       Date:  2015-10-19       Impact factor: 9.867

Review 5.  The bowel and beyond: the enteric nervous system in neurological disorders.

Authors:  Meenakshi Rao; Michael D Gershon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-07-20       Impact factor: 46.802

6.  Bone morphogenetic protein regulation of enteric neuronal phenotypic diversity: relationship to timing of cell cycle exit.

Authors:  Alcmène Chalazonitis; Tuan D Pham; Zhishan Li; Daniel Roman; Udayan Guha; William Gomes; Lixin Kan; John A Kessler; Michael D Gershon
Journal:  J Comp Neurol       Date:  2008-08-10       Impact factor: 3.215

Review 7.  Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.

Authors:  S M Matt; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-11       Impact factor: 4.147

8.  Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.

Authors:  M Rieck; A F Schumacher-Schuh; V Altmann; S M Callegari-Jacques; C R M Rieder; M H Hutz
Journal:  Pharmacogenomics J       Date:  2016-10-25       Impact factor: 3.550

9.  Role of Dopamine and D2 Dopamine Receptor in the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Ganna Tolstanova; Xiaoming Deng; Amrita Ahluwalia; Brankica Paunovic; Alona Prysiazhniuk; Lyudmyla Ostapchenko; Andrzej Tarnawski; Zsuzsanna Sandor; Sandor Szabo
Journal:  Dig Dis Sci       Date:  2015-05-14       Impact factor: 3.199

10.  Essential roles of enteric neuronal serotonin in gastrointestinal motility and the development/survival of enteric dopaminergic neurons.

Authors:  Zhishan Li; Alcmène Chalazonitis; Yung-Yu Huang; J John Mann; Kara Gross Margolis; Qi Melissa Yang; Dolly O Kim; Francine Côté; Jacques Mallet; Michael D Gershon
Journal:  J Neurosci       Date:  2011-06-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.